Reports
Sale
Soft Tissue Sarcoma Market Size, Share, Growth, Analysis: By Treatment Type: Radiation Therapy, Anti-Angiogenesis, Chemotherapy, Targeted Therapy, Others; By Route of Administration: Oral, Parenteral, Others; By End Users Hospitals, Homecare, Specialty Clinics, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Soft Tissue Sarcoma Market Outlook
The soft tissue sarcoma market size is expected to grow at a CAGR of 5.5% during the forecast period of 2024-2032. The market is driven by the rising number of cancer patients and the growing demand for targeted therapies to treat soft tissue sarcoma across the 8 major markets.
Soft Tissue Sarcoma Market Overview
Soft tissue sarcoma is a cancer subtype that develops in soft tissues such as muscle, fat, tendons, and nerves. They represent 1% of all cancers that occur in adults . According to the American Cancer Society, 13,590 individuals will be diagnosed with soft tissue sarcoma in 2024, out of which 7,700 will be males and the rest 5,890 will be females. It is also predicted that it will cause mortality in 5,200 people. The growing number of patients with this rare type of cancer is expected to fuel the soft tissue sarcoma market growth.
The emergence of novel therapies to treat soft tissue sarcoma is also aiding the market growth. In the 2023 American Society of Clinical Oncology Annual Meeting, it was revealed that the combination of doxorubicin, balstilimab, and zalifrelimab demonstrated efficacy as well as favorable 6-month progression-free survival (PFS) rates in patients soft tissue sarcoma. The introduction of such treatment alternatives with manageable toxicity is anticipated to increase the soft tissue sarcoma market demand.
The market is projected to experience significant growth supported by the increasing adoption of targeted therapies along with the continued advancements in the drug pipelines throughout the forecast period. The rising healthcare expenditure and heightened patient awareness will also propel the market size.
Soft Tissue Sarcoma Market Trends
| Key Trends | Description |
| Increasing Incidence of Soft Tissue Sarcoma | Soft tissue sarcoma, although rare, accounts for 1% of all adult cancers. It is predicted to affect 13,590 new individuals in 2024 (7,700 males and 5,890 females) |
| Emergence of Novel Therapies | Novel treatment alternatives such as combination therapies are being increasingly adopted to treat the condition in a wide section of patients, having different symptoms for the condition. |
| Increasing Adoption of Targeted Therapies and Advancements in Drug Pipelines | The soft tissue sarcoma market is experiencing growth due to the increasing adoption of targeted therapies and continuous advancements in drug pipelines. These developments offer promising treatment options for patients. |
| Rising Healthcare Expenditure and Patient Awareness | The market is projected to grow with the rise in healthcare expenditure and heightened patient awareness about soft tissue sarcoma. |
Soft Tissue Sarcoma Market Segmentation
Market Breakup by Treatment Type
- Radiation Therapy
- Anti-Angiogenesis
- Chemotherapy
- Targeted Therapy
- Others
Soft tissue sarcoma treatment includes radiation therapy, anti-angiogenesis agents, chemotherapy, targeted therapy, and other interventions. This segmentation outlines the range of therapeutic approaches employed to manage soft tissue sarcoma effectively with minimum adverse effects.
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Based on the route of administration, the soft tissue sarcoma market includes oral, parenteral, and others. In oral administration, medications are taken by mouth. Parenteral administration involves injections or infusions, to provide immediate therapeutic effect.
Market Breakup by End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
The market segmentation by end users comprises hospitals, homecare, and specialty clinics, among others. Hospitals act as the primary centres for the diagnosis and treatment of soft tissue sarcoma patients.
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online pharmacy
- Others
Distribution channels in the market include hospital pharmacies, retail pharmacies, and online pharmacies, among others. This distribution network enhances accessibility, catering to the diverse needs of the patients.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The market segmentation on a regional basis offers insights into the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America covers a significant portion of the market segment. This can be attributed to the rising prevalence of soft skin sarcoma and the growing demand for targeted therapies in the region.
Soft Tissue Sarcoma Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Endo International PLC
- Dr. Reddy's Laboratories Ltd
- Lupin
- Aurobindo Pharma
- Sun Pharmaceutical Industries Ltd.
- Merck & Co.
- Lilly
- Bayer AG
- Novartis AG
- GlaxoSmithKline PLC
- Pfizer Inc
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- F. Hoffmann-La Roche Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End Users |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Soft Tissue Sarcoma Market Report
- How has the soft tissue sarcoma market performed so far and how is it expected to evolve in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- What is the epidemiology and incidence of soft tissue sarcoma?
- How does the prevalence and incidence of soft tissue sarcoma affect the market landscape?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited soft tissue sarcoma market growth during the forecast period?
- What treatment type of soft tissue sarcoma will dominate the market share?
- What are the prominent diagnostic methods and tools used in the detection and monitoring of soft tissue sarcoma?
- Which drugs are likely to arrive in the market during the forecast period?
- What key research initiatives are expected to boost the market value during the forecast period?
- What are the factors driving regional disparities in soft tissue sarcoma treatment and outcomes?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Soft Tissue Sarcoma Market Overview – 8 Major Markets
3.1 Soft Tissue Sarcoma Market Historical Value (2017-2023)
3.2 Soft Tissue Sarcoma Market Forecast Value (2024-2032)
4 Soft Tissue Sarcoma Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Therapy Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Therapy Success Rate
6 Soft Tissue Sarcoma Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
6.3 EU-4 and United Kingdom Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
6.3.1 Germany Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
6.3.2 France Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
6.3.3 Italy Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
6.3.4 Spain Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
6.3.5 United Kingdom Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
6.4 Japan Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
6.5 India Soft Tissue Sarcoma Epidemiology Forecast (2017-2032)
7 Soft Tissue Sarcoma Market Landscape-8 Major Markets
7.1 Soft Tissue Sarcoma Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Soft Tissue Sarcoma Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
8 Soft Tissue Sarcoma Therapy Challenges and Unmet Needs
8.1 Therapy Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Therapy
10 Soft Tissue Sarcoma Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Soft Tissue Sarcoma Market Segmentation-8 Major Markets
11.1 Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
11.1.1 Market Overview
11.1.2 Radiation Therapy
11.1.3 Anti-Angiogenesis
11.1.4 Chemotherapy
11.1.5 Targeted Therapy
11.1.6 Others
11.2 Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Parenteral
11.2.4 Others
11.3 Soft Tissue Sarcoma Market (2017-2032) by End Users
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Homecare
11.3.4 Specialty Clinics
11.3.5 Others
11.4 Soft Tissue Sarcoma Market (2017-2032) by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online pharmacy
11.4.5 Others
11.5 Soft Tissue Sarcoma Market (2017-2032) by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
11.5.5 India
12 United States Soft Tissue Sarcoma Market (2017-2032)
12.1 United States Soft Tissue Sarcoma Market Historical Value (2017-2023)
12.2 United States Soft Tissue Sarcoma Market Forecast Value (2024-2032)
12.3 United States Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
12.3.1 Market Overview
12.3.2 Radiation Therapy
12.3.3 Anti-Angiogenesis
12.3.4 Chemotherapy
12.3.5 Targeted Therapy
12.3.6 Others
12.4 Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
12.4.1 Market Overview
12.4.2 Oral
12.4.3 Parenteral
12.4.4 Others
13 EU-4 and United Kingdom Soft Tissue Sarcoma Market
13.1 EU-4 and United Kingdom Soft Tissue Sarcoma Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Soft Tissue Sarcoma Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Soft Tissue Sarcoma Market Overview
13.4 EU-4 and United Kingdom Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
13.4.1 Market Overview
13.4.2 Radiation Therapy
13.4.3 Anti-Angiogenesis
13.4.4 Chemotherapy
13.4.5 Targeted Therapy
13.4.6 Others
13.5 EU-4 and United Kingdom Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
13.5.1 Market Overview
13.5.2 Oral
13.5.3 Parenteral
13.5.4 Others
14 Japan Soft Tissue Sarcoma Market
14.1 Japan Soft Tissue Sarcoma Market Historical Value (2017-2023)
14.2 Japan Soft Tissue Sarcoma Market Forecast Value (2024-2032)
14.3 Japan Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
14.3.1 Market Overview
14.3.2 Radiation Therapy
14.3.3 Anti-Angiogenesis
14.3.4 Chemotherapy
14.3.5 Targeted Therapy
14.3.6 Others
14.4 Japan Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Parenteral
14.4.4 Others
15 India Soft Tissue Sarcoma Market
15.1 India Soft Tissue Sarcoma Market Historical Value (2017-2023)
15.2 India Soft Tissue Sarcoma Market Forecast Value (2024-2032)
15.3 India Soft Tissue Sarcoma Market (2017-2032) by Treatment Type
15.3.1 Market Overview
15.3.2 Radiation Therapy
15.3.3 Anti-Angiogenesis
15.3.4 Chemotherapy
15.3.5 Targeted Therapy
15.3.6 Others
15.4 India Soft Tissue Sarcoma Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Parenteral
15.4.4 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 JAPAN PMDA
16.1.4 India CDSCO
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Endo International PLC
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Dr. Reddy's Laboratories Ltd
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Lupin
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Aurobindo Pharma
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Sun Pharmaceutical Industries Ltd.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Merck & Co.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Lilly
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Bayer AG
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Novartis AG
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 GlaxoSmithKline PLC
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Pfizer Inc
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Sanofi
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Teva Pharmaceutical Industries Ltd.
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 Mylan N.V.
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 F. Hoffmann-La Roche Ltd.
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
List not exhaustive
23 Soft Tissue Sarcoma Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.5% during the forecast period of 2024-2032, driven by the increasing number of cancer patients and demand for targeted therapies to treat soft tissue sarcoma across the 8 major markets.
The emergence of novel therapies to treat soft tissue sarcoma and the increased healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is the rise in strategic partnerships among the key market players to address the growing demand of the market.
Based on the route of administration, the market includes oral, parenteral, and others.
Soft tissue sarcoma treatment includes radiation therapy, anti-angiogenesis agents, chemotherapy, targeted therapy, and others.
The market segmentation by end users comprises hospitals, homecare, and specialty clinics, among others.
Distribution channels in the market include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.
Key players involved in the market are Endo International PLC, Dr. Reddy's Laboratories Ltd, Lupin, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Merck & Co., Lilly, Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc, Sanofi, Teva Pharmaceutical Industries Ltd., Mylan N.V., and F. Hoffmann-La Roche Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER